salivaricin A: from Streptococcus salivarius; MW 2315 kDa; 22-residue peptide containing one lanthionine & two beta-methyllanthionine residues; amino acid sequence given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 172832 |
| SCHEMBL ID | 526308 |
| MeSH ID | M0220210 |
| Synonym |
|---|
| einecs 275-615-2 |
| salivaricin a |
| cyclotetrasiloxane, 2,4,6,8-tetramethyl-2,4,6,8-tetrakis(3-acryloxypropyl)- |
| 71550-64-6 |
| 2,4,6,8-tetramethyl-2,4,6,8-tetrakis(3-acryloyloxypropyl) cyclotetrasiloxane |
| (2,4,6,8-tetramethylcyclotetrasiloxane-2,4,6,8-tetrayl)tetrakis(propane-1,3-diyl) tetraacrylate |
| 2-propenoic acid, 1,1',1'',1'''-((2,4,6,8-tetramethylcyclotetrasiloxane-2,4,6,8-tetrayl)tetra-3,1-propanediyl) ester |
| 2-propenoic acid, (2,4,6,8-tetramethylcyclotetrasiloxane-2,4,6,8-tetrayl)tetra-3,1-propanediyl ester |
| SCHEMBL526308 |
| 3-{2,4,6,8-tetramethyl-4,6,8-tris[3-(prop-2-enoyloxy)propyl]-1,3,5,7,2,4,6,8-tetraoxatetrasilocan-2-yl}propyl prop-2-enoate |
| (2,4,6,8-tetramethyl-1,3,5,7,2,4,6,8-tetroxatetrasilocane-2,4,6,8-tetrayl)tetra(propane-3,1-diyl) tetraprop-2-enoate |
| DTXSID70992100 |
| (2,4,6,8-tetramethyl-1,3,5,7,2,4,6,8-tetraoxatetrasilocane-2,4,6,8-tetrayl)tetrakis(propane-3,1-diyl) tetraacrylate |
| (2,4,6,8-tetramethyl-1,3,5,7,2,4,6,8-tetraoxatetrasilocane-2,4,6,8-tetrayl)tetrakis(propane-3,1-diyl)tetraacrylate |
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine whether dosing with bacteriocin-producing Streptococcus salivarius following an antimicrobial mouthwash effects a change in oral malodour parameters and in the composition of the oral microbiota of subjects with halitosis." | ( A preliminary study of the effect of probiotic Streptococcus salivarius K12 on oral malodour parameters. Burton, JP; Chilcott, CN; Moore, CJ; Speiser, G; Tagg, JR, 2006) | 0.33 |
| "The colonization efficacies of salivaricin A (SalA)-producing Streptococcus salivarius strains 20P3 and 5 were compared when given in milk to 219 children, using either 2-day or 9-day dosing regimens." | ( The effect of ingestion of milk supplemented with salivaricin A-producing Streptococcus salivarius on the bacteriocin-like inhibitory activity of streptococcal populations on the tongue. Dierksen, KP; Inglis, M; Moore, CJ; Tagg, JR; Wescombe, PA, 2007) | 0.88 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (14.29) | 18.2507 |
| 2000's | 10 (47.62) | 29.6817 |
| 2010's | 6 (28.57) | 24.3611 |
| 2020's | 2 (9.52) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.67) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (4.76%) | 5.53% |
| Reviews | 2 (9.52%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 18 (85.71%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||